Phase 1 and 2 studies of trimetrexate administered in combination with fluorouracil to patients with metastatic cancer
Hudes, G.R.; Comis, R.L.
Seminars in Oncology 15(2 Suppl 2: 41-45
1988
ISSN/ISBN: 0093-7754 PMID: 2966984 Document Number: 315062
Document emailed within 1 workday
Related Documents
Yamaguchi, Y.; Minami, K.; Kawabuchi, Y.; Emi, M. 2006: A phase I trial of CPT-11 in combination with 5-fluorouracil plus leucovorin chemotherapy for patients with metastatic colorectal cancer Hepato-Gastroenterology 53(68): 201-205Bowen, D.; Johnson, D.H.; Southerland, W.M.; Hughes, D.E.; Hawkins, M. 1999: Selectivity in human breast cancer and human bone marrow using trimetrexate in combination with 5-fluorouracil Anticancer Research 19(5b): 3837-3840
Stewart, J.A. 1988: Safety and tolerance of trimetrexate: results of a phase II multicenter study in patients with metastatic cancer refractory to conventional therapy or for which no conventional therapy exists Seminars in Oncology 15(2 Suppl. 2): 10-16
Speyer, J.L.; Collins, J.M.; Dedrick, R.L.; Brennan, M.F.; Buckpitt, A.R.; Londer, H.; DeVita, V.T.; Myers, C.E. 1980: Phase i and pharmacological studies of 5-fluorouracil administered intraperitoneally Cancer Research 40(3): 567-572
Reece, P.A.; Morris, R.G.; Bishop, J.F.; Olver, I.N.; Raghavan, D. 1987: Pharmacokinetics of trimetrexate administered by five-day continuous infusion to patients with advanced cancer Cancer Research 47(11): 2996-2999
Slee, P.H.T.J.; Rodenburg, C.J.; Nortier, J.W.R.; van Bochove, A. 2004: A phase i dose-escalating study of docetaxel plus folinic acid and 5-fluorouracil in anthracycline-pretreated patients with metastatic breast cancer Netherlands Journal of Medicine 62(9): 314-319
Van Cutsem, E.; Blijham, G.H. 1999: Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group Seminars in Oncology 26(1 Suppl. 5): 13-20
Fanucchi, M.P.; Walsh, T.D.; Fleisher, M.; Lokos, G.; Williams, L.; Cassidy, C.; Vidal, P.; Chou, T.C.; Niedzwiecki, D.; Young, C.W. 1987: Phase i and clinical pharmacology study of trimetrexate administered weekly for three weeks Cancer Research 47(12): 3303-3308
Grem, J.L.; McAtee, N.; Steinberg, S.M.; Hamilton, J.M.; Murphy, R.F.; Drake, J.; Chisena, T.; Balis, F.; Cysyk, R.; Arbuck, S.G. 1993: A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma Cancer Research 53(20): 4828-4836
Nicholson, B.; Paul, D.; Shyr, Y.; Garrett, M.; Hande, K.R.; Johnson, D.H. 1997: Paclitaxel/5-fluorouracil/leucovorin in metastatic breast cancer: a Vanderbilt Cancer Center phase Ii trial Seminars in Oncology 24(4 Suppl 11: S11
Maoleekoonpairoj, S. 1995: Combination 5-fluorouracil (5-FU) and alpha interferon (IFN) in metastatic colorectal cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(Suppl 3): 285
Ohtani, H.; Arimoto, Y.; Nishio, K.; Kanamiya, Y.; Oba, H.; Adachi, K.; Shintani, M.; Nakamura, R.; Yui, S. 2008: Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies Gan to Kagaku Ryoho. Cancer and ChemoTherapy 35(10): 1769-1774
Halim, A.; Wahba, H. 2012: Cisplatin-ifosfamide combination chemotherapy in metastatic triple-negative, anthracycline- and taxane-pretreated breast cancer patients; a phase II study Journal of BUON: Official Journal of the Balkan Union of Oncology 17(2): 254-258
Chauffert, B.; Bonnotte, B.; Chvetzoff, G.; Flesch, M. 1998: The major response of metastatic kidney cancer to the combination of oxaliplatin, 5-fluorouracil and folinic acid (FOX-FOL) Presse Medicale 27(18): 859
Muthalib, A.; Darwis, I.; Prayogo, N.; Sutjipto 2000: Preliminary results of multicenter phase Ii trial of docetaxel (Taxotere) in combination with doxorubicin as first line chemotherapy in Indonesian patients with advanced or metastatic breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(Suppl 2): 498-504
Cerea, G.; Vaghi, M.; Ardizzoia, A.; Villa, S.; Bucovec, R.; Mengo, S.; Gardani, G.; Tancini, G.; Lissoni, P. 2003: Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations Anticancer Research 23(2c): 1951-1954
Klaassen, U.; Harstrick, A.; Wilke, H.; Seeber, S. 1996: Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer Seminars in Oncology 23(1 Suppl 1: 44-47
Yamamoto, M.; Furuse, K.; Fukuoka, M.; Kawahara, M.; Arai, R.; Kodama, N.; Takada, M.; Negoro, S.; Matsui, K.; Ryu, S. 1988: Phase Ii studies of a single agent and a cis-platinum-based two-drug combination in patients with non-small cell lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(3): 487-492
Bria, E.; Vanni, B.; Cuppone, F.; Calabretta, F.; Campanella, C.; Torsello, A.; Terzoli, E. 2004: Metastatic breast cancer: is global survival increase a realistic endpoint in phase III clinical trials? Studies on taxanes; studies on trastuzumab I Supplementi di Tumori: Official Journal of Societa Italiana di Cancerologia . 3(4): S65-S66
Remick, S.C.; Grem, J.L.; Fischer, P.H.; Tutsch, K.D.; Alberti, D.B.; Nieting, L.M.; Tombes, M.B.; Bruggink, J.; Willson, J.K.; Trump, D.L. 1990: Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion Cancer Research 50(9): 2667-2672